Nutritional status and bioelectrical phase angle assessment in adult Crohn disease patients receiving anti-TNFα therapy

Digestive and Liver Disease

Volumn 49, Issue 5, 2017, Pages 495-499

  Emerenziani, Sara ^a   Biancone, Livia ^b   Guarino, Michele Pier Luca ^a   Balestrieri, Paola ^a   Stasi, Elisa ^b   Ribolsi, Mentore ^a   Rescio, Maria Paola ^a   Altomare, Annamaria ^a   Cocca, Silvia ^a   Pallone, Francesco ^b   Cicala, Michele ^a  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Biologic and conventional therapies; Body composition; Crohn's disease; Malnutrition; Nutritional status

Indexed keywords

ALBUMIN; AMINOSALICYLIC ACID DERIVATIVE; ANTIBIOTIC AGENT; AZATHIOPRINE; C REACTIVE PROTEIN; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; PREDNISOLONE; STEROID; TUMOR NECROSIS FACTOR;

ADULT; ALBUMIN BLOOD LEVEL; ANTIBIOTIC THERAPY; ARTICLE; BIOELECTRICAL IMPEDANCE ANALYSIS; BIOLOGICAL THERAPY; BODY COMPOSITION; BODY COMPOSITION ANALYZER; BODY MASS; CLINICAL ARTICLE; CLINICAL ASSESSMENT TOOL; CLINICAL EVALUATION; CLINICAL OUTCOME; COMPARATIVE STUDY; CONTROLLED STUDY; CORTICOSTEROID THERAPY; CROHN DISEASE; CROHN DISEASE ACTIVITY INDEX; DIAGNOSTIC TEST ACCURACY STUDY; FAT FREE MASS; FEMALE; FOLLOW UP; HUMAN; HYPOALBUMINEMIA; IMMUNOSUPPRESSIVE TREATMENT; MAINTENANCE THERAPY; MALE; MALNUTRITION; MIDDLE AGED; NUTRITIONAL ASSESSMENT; NUTRITIONAL STATUS; PHASE ANGLE; PORTABLE EQUIPMENT; PRIORITY JOURNAL; PROGNOSTIC ASSESSMENT; PROSPECTIVE STUDY; TREATMENT RESPONSE; ANTAGONISTS AND INHIBITORS; CASE CONTROL STUDY; COMPLICATION; IMPEDANCE; ITALY; SEVERITY OF ILLNESS INDEX;

ADULT; BODY COMPOSITION; BODY MASS INDEX; CASE-CONTROL STUDIES; CROHN DISEASE; ELECTRIC IMPEDANCE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFLIXIMAB; ITALY; MALE; MALNUTRITION; MIDDLE AGED; NUTRITION ASSESSMENT; NUTRITIONAL STATUS; SEVERITY OF ILLNESS INDEX; TUMOR NECROSIS FACTOR-ALPHA;

EID: 85009352840     PISSN: 15908658     EISSN: 18783562     Source Type: Journal    
DOI: 10.1016/j.dld.2016.12.026     Document Type: Article

References (23)

1. [1] Mijac, D.D., Janković, G.L., Jorga, J., et al. Nutritional status in patients with active inflammatory bowel disease: prevalence of malnutrition and methods for routine nutritional assessment. European Journal of Internal Medicine 21 (2010), 315–319.
2. [2] Gassull, M.A., Nutrition and inflammatory bowel disease: its relation to pathophysiology, outcome and therapy. Digestive Diseases 21 (2003), 220–227.
3. [3] Goh, J., O'Morain, C.A., Review article: nutrition and adult inflammatory bowel disease. Alimentary Pharmacology and Therapeutics 17 (2003), 307–320.
4. [4] Capristo, E., Addolorato, G., Mingrone, G., et al. Effect of disease localization on the anthropometric and metabolic features of Crohn's disease. The American Journal of Gastroenterology 93 (1998), 2411–2419.
5. [5] Alastair, F., Emma, G., Emma, P., Nutrition in inflammatory bowel disease. JPEN. Journal of Parenteral and Enteral Nutrition 35 (2011), 571–580.
6. [6] Bryant, R., Trott, Bartholomeusz, F., et al. Systematic review: body composition in adults with inflammatory bowel disease. Alimentary Pharmacology and Therapeutics 38 (2013), 213–225.
7. [7] Lukaski, H.C., Johnson, P.E., Bolonchuk, W.W., et al. Assessment of fat-free mass using bioelectrical impedance measurements of the human body. The American Journal of Clinical Nutrition 41 (1985), 810–817.
8. [8] Norman, K., Stobaus, N., Pirlich, M., et al. Bioelectrical phase angle and impedance vector analysis—clinical relevance and applicability of impedance parameters. Clinical Nutrition 31 (2012), 854–861.
9. [9] Norman, K., Kirchner, H., Lochs, H., et al. Malnutrition affects quality of life in gastroenterology patients. World Journal of Gastroenterology 12 (2006), 3380–3385.
10. [10] Gupta, D., Lis, C.G., Dahlk, S.L., et al. Bioelectrical impedance phase angle as a prognostic indicator in advanced pancreatic cancer. The British Journal of Nutrition 92 (2004), 957–962.
11. [11] Werkstetter, K.J., Ullrich, J., Schatz, S.B., et al. Lean body mass, physical activity and quality of life in paediatric patients with inflammatory bowel disease and in healthy controls. Journal of Crohn's and Colitis 6 (2012), 665–673.
12. [12] Targan, S.R., Hanauer, S.B., van Deventer, S.J., et al. A short term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn disease cA2 Study Group. The New England Journal of Medicine 337 (1997), 1029–1035.
13. [13] Hanauer, S.B., Feagan, B.G., Lichtenstein, G.R., et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomized trial. Lancet 359 (2002), 1541–1549.
14. [14] Travis, S., Van Assche, G., Dignass, A., et al. On the second ECCO Consensus on Crohn's disease. Journal of Crohn's and Colitis 4 (2010), 1–6.
15. [15] Best, W.R., Becktel, J.M., Singleton, J.W., et al. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 70 (1976), 439–444.
16. [16] World Health Organization (WHO), Physical status: the use and interpretation of anthropometry. Report of a WHO Expert Committee. World Health Organization Technical Report Series 854 (1995), 1–452.
17. [17] Thayu, M., Denson, L.A., Shults, J., et al. Determinants of changes in linear growth and body composition in incident pediatric Crohn's disease. Gastroenterology 139 (2010), 430–438.
18. [18] Vespasiani Gentilucci, U., Caviglia, R., Picardi, A., et al. Infliximab reverses growth hormone resistance associated with inflammatory bowel disease. Alimentary Pharmacology and Therapeutics 21 (2005), 1063–1071.
19. [19] Merola, E., Mattioli, E., Minimo, C., et al. Immunohistochemical evaluation of pRb2/p130, VEGF, EZH2, p53, p16, p21 waf-1, p27, and PCNA in Barrett's esophagus. Journal of Cellular Physiology 207 (2006), 512–519.
20. [20] Valentini, L., Schaper, L., Buning, C., et al. Malnutrition and impaired muscle strength in patients with Crohn's disease and ulcerative colitis in remission. Nutrition 24 (2008), 694–702.
21. [21] Lochs, H., Dejong, C., Hammarqvist, F., et al. ESPEN guidelines on enteral nutrition: gastroenterology. Clinical Nutrition 25 (2006), 260–274.
22. [22] Wiese, D., Lashner, B., Seidner, D., Measurement of nutrition status in Crohn's disease patients receiving infliximab therapy. Nutrition in Clinical Practice 23 (2008), 551–556.
23. [23] Nakahigashi, M., Yamamoto, T., Increases in body mass index during infliximab therapy in patients with Crohn's disease: an open label prospective study. Cytochine 56 (2011), 531–535.